Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen (NASDAQ: OCGN) priced $115.0 million aggregate principal amount of 6.75% convertible senior notes due 2034 in a private Rule 144A offering, with a 13-day option for an additional $15.0 million. The notes sold at 90% of principal.
Ocugen expects closing on May 7, 2026, with estimated net proceeds of approximately $99.5 million (or $112.6 million if the option is exercised). Approximately $32.7 million of net proceeds are planned to repay the Avenue loan; remaining proceeds are for general corporate purposes. Initial conversion price is approximately $2.68 per share (372.7866 shares per $1,000), convertible after May 15, 2027 or upon the reserved share effective date.
Ocugen (NASDAQ: OCGN) announced a proposed private offering of $115 million aggregate principal of Convertible Senior Notes due 2034, with an initial purchaser option for an additional $15 million. Ocugen intends to use approximately $32.7 million of net proceeds to repay a loan and related fees; remaining proceeds for general corporate purposes. Terms including interest rate and conversion rate will be set at pricing. Notes will be unsecured, rank junior to secured debt to the extent of secured assets, and may be converted into cash, shares, or a combination at Ocugen's election. The offering is to qualified institutional buyers under Rule 144A and is subject to market conditions.
Ocugen (NASDAQ: OCGN) will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, May 5, 2026 to discuss first quarter 2026 financial results and provide a business update. A pre-market earnings announcement will be issued the same day.
Dial-in numbers: U.S. (800) 715-9871; International (646) 307-1963; Conference ID: 4973685. The webcast and replay will be available on the Ocugen investor site events section.
Ocugen (NASDAQ: OCGN) will present at two industry investor conferences the week of April 27–29, 2026. Dr. Shankar Musunuri will present at Oppenheimer’s Innovation on the Island in Puerto Rico on April 28 at 8:20 a.m. AST; Abhi Gupta will present at Meeting on the Med in Rome on April 28 at 4:30 p.m. CEST. Executive leadership will discuss the company’s modifier gene therapy platform and remarks note a planned BLA submission for OCU400 later this year.
Ocugen (NASDAQ: OCGN) announced early completion of dosing in the Phase 2/3 GARDian3 pivotal trial for OCU410ST in Stargardt disease with N=63 enrolled in under nine months. Topline results are expected in 2Q27 and a BLA filing is planned by mid-2027. The single-dose subretinal therapy (3 × 1010 vg/eye) showed no serious adverse events reported to date and aims to slow atrophic lesion growth and preserve visual function.
Ocugen (NASDAQ: OCGN)/b) reported positive 12-month Phase 2 ArMaDa results for in geographic atrophy (GA) secondary to dry AMD. The medium (optimal) dose showed a 31% reduction in lesion growth versus control (p<0.05) and 27% slower ellipsoid zone loss, with no OCU410-related serious adverse events reported. The 51-patient trial randomized subjects 1:1:1 (medium, high, control). Ocugen plans a Phase 3 registrational trial in Q3 2026 with up to 300 subjects and an adaptive design powered >95%.
Ocugen (NASDAQ: OCGN) will host a live webcast and conference call at 8:00 a.m. EDT on Tuesday, March 24, 2026 to discuss full Phase 2 ArMaDa clinical trial data for OCU410, a modifier gene therapy for geographic atrophy (late-stage dry AMD).
Key opinion leaders and Ocugen executives will present; a replay and archived webcast will be available on the company investor site. Dial-in and webcast details provided for attendees.
Ocugen (NASDAQ: OCGN) reported Q4 and full‑year 2025 results and a business update focused on three modifier gene therapy programs targeting BLAs over the next three years.
Key developments: completed enrollment (140 patients) in the Phase 3 OCU400 liMeliGhT trial with topline data expected Q1 2027 and a planned rolling BLA in Q3 2026; positive 12‑month OCU410 Phase 2 data (46% lesion growth reduction; p=0.015; N=23); exclusive Korean license for OCU400; $18.9M cash at year‑end and $22.5M financing in Jan 2026 extending runway into Q4 2026.
Ocugen (NASDAQ: OCGN) completed enrollment for the Phase 3 liMeliGhT trial of OCU400 in broad retinitis pigmentosa, randomizing 140 patients 2:1 into treated and untreated control arms. Topline Phase 3 data are expected in 1Q 2027, supporting a planned rolling BLA and potential approval in 2027.
Three‑year Phase 1/2 data show durable safety and tolerability, ~2‑line LLVA gain and 88% (7/8) evaluable treated subjects with improvement or preservation versus untreated eyes.
Ocugen (NASDAQ: OCGN) will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to discuss fourth quarter and full year 2025 financial results and provide a business update.
A pre-market earnings announcement will be issued the same day. Dial-in numbers, conference ID, and a webcast link will be available on the company investor site; a replay and archived webcast will follow.